Comparison of an Fcab-Drug Conjugate with Other Antibody-Drug Conjugate Formats towards Exposure and Antitumor Activity
Bioconjugate Chemistry · 2026
DOI: 10.1021/acs.bioconjchem.6c00324 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Bioconjugate Chemistry, 2026. Verfasst von Sebastian Jäger und 11 weiteren Autor:innen. Beteiligte Einrichtung: ADCs & Targeted NBE Therapeutics, Merck Healthcare KGaA, 64293Darmstadt, Germany. Hauptthemen laut MEDLINE: Immunoconjugates, Immunoglobulin Fc Fragments, Antineoplastic Agents. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Sigrid Jusélius Foundation, Merck Healthcare KGaA, Cancer Society of Finland.
Abstract (Originalsprache)
Antibody-drug conjugates (ADCs) based on Fc antigen-binding fragments (Fcabs) promise improved tumor penetration while retaining the FcRn-mediated long half-life. Building on prior spheroid studies, we directly compared a 50 kDa HER2-targeted Fcab-MMAE ADC with a matched 150 kDa control molecule (aDIG-Fcab-MMAE) consisting of the same HER2-targeting Fcab ADC equipped with additional non-targeting anti-digoxigenin (aDIG) Fab arms and trastuzumab Fab- and IgG-based ADCs (50 kDa T-Fab-MMAE and 150 kDa T-IgG-MMAE) using the same linker-payloads. Site-specific conjugation yielded high-purity DAR2 species with excellent serum stability. In vitro cytotoxicity assays revealed that Fcab-MMAE and aDIG-Fcab-MMAE exhibited lower potency compared to T-Fab-MMAE and T-IgG-MMAE, correlating with their approximately 10-fold lower binding affinity for HER2. A pharmacokinetic study in mice showed similar exposure for the Fcab-MMAE, its 150 kDa control, and a higher exposure for T-IgG-MMAE ADC, while the T-Fab-MMAE ADC cleared rapidly. In an NCI-N87 gastric cancer SCID mouse xenograft model, T-IgG-MMAE demonstrated superior efficacy, while Fcab-MMAE and aDIG-Fcab-MMAE showed similar efficacy despite their size difference, with T-Fab-MMAE showing lower efficacy. These data indicate that at similar exposure, reduced scaffold size alone may not improve in vivo efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ADCs & Targeted NBE Therapeutics, Merck Healthcare KGaA, 64293Darmstadt, Germany.
- Innovative Bioanalytics, New Biological Entities, Drug Metabolism and Pharmacokinetics (NBE-DMPK), Research and Development, Merck Healthcare KGaA, RBM S.p.A.-Istituto di Ricerche Biomediche 'A. Marxer,' an Affiliate of…
- Early Protein Supply & Characterization, Merck Healthcare KGaA, 64293Darmstadt, Germany.
- Laboratory of Molecular Oncology, Biomedicum, University of Helsinki, 00290Helsinki, Finland.
- Helsinki University Hospital and University of Helsinki, 00290Helsinki, Finland.
- Department of Oncology, Helsinki University Hospital and University of Helsinki, 00290Helsinki, Finland.
ORCID-Profile: Sebastian Jäger, Birgit Piater, Stephan Dickgiesser, Christian Schröter
Förderung
- Sigrid Jusélius Foundation
- Merck Healthcare KGaA
- Cancer Society of Finland
- Sigrid Jus?lius Foundation
Zitieren
APA
Jäger, S., Piater, B., Dickgiesser, S., Tonillo, J., Hecht, S., Anderl, J., Minelli, F., Bertotti, E., Rasche, N., Joensuu, H., Barok, M., & Schröter, C. (2026). Comparison of an Fcab-Drug Conjugate with Other Antibody-Drug Conjugate Formats towards Exposure and Antitumor Activity. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.6c00324
Vancouver
Jäger S, Piater B, Dickgiesser S, Tonillo J, Hecht S, Anderl J, et al. Comparison of an Fcab-Drug Conjugate with Other Antibody-Drug Conjugate Formats towards Exposure and Antitumor Activity. Bioconjugate Chemistry. 2026. doi:10.1021/acs.bioconjchem.6c00324
BibTeX
@article{Jger2026,
author = {Jäger, Sebastian and Piater, Birgit and Dickgiesser, Stephan and Tonillo, Jason and Hecht, Stefan and Anderl, Jan and Minelli, Francesca and Bertotti, Elisa and Rasche, Nicolas and Joensuu, Heikki and Barok, Mark and Schröter, Christian},
title = {Comparison of an Fcab-Drug Conjugate with Other Antibody-Drug Conjugate Formats towards Exposure and Antitumor Activity},
journal = {Bioconjugate Chemistry},
year = {2026},
doi = {10.1021/acs.bioconjchem.6c00324}
}
EUVIMED